Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

Clinical Cancer Research

Volumn 13, Issue 5, 2007, Pages 1576-1583

  Yeh, Tammie C ^a   Marsh, Vivienne ^a   Bernat, Bryan A ^a   Ballard, Josh ^a   Colwell, Heidi ^a   Evans, Ron J ^a   Parry, Janet ^a   Smith, Darin ^a   Brandhuber, Barbara J ^a   Gross, Stefan ^a   Marlow, Allison ^a   Hurley, Brian ^a   Lyssikatos, Joe ^a   Lee, Patrice A ^a   Winkler, James D ^a   Koch, Kevin ^a   Wallace, Eli ^a  

^a ARRAY BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARRY 142886; AZD 6244; B RAF KINASE; ENZYME INHIBITOR; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHORBOL 13 ACETATE 12 MYRISTATE; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLORECTAL TUMOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION;

ANIMALS; BENZIMIDAZOLES; BLOTTING, WESTERN; CELL PROLIFERATION; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33947401129     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1150     Document Type: Article

References (36)

1. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355-65.
2. Choong NW, Ma PC, Salgia R. Therapeutic targeting of receptor tyrosine kinases in lung cancer. Expert Opin Ther Targets 2005;9:533-59.
3. Porter AC, Vaillancourt RR. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 1998;17:1343-52.
4. Robertson SC, Tynan J, Donoghue DJ. RTK mutations and human syndromes: when good receptors turn bad. Trends Genet 2000;16:368.
5. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
6. Gray-Schopfer VC, da Rocha Dias S, Marais R. The role of B-RAF in melanoma. Cancer Metastasis Rev 2005;24:165-83.
7. Fransen K, Klintenas M, Osterstrom A, Dimberg J, Monstein HJ, Soderkvist P. Mutation analysis of the BRAF, ARAF, and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004;25:527-33.
8. Friday BB, Adjei AA. K-ras as a target for cancer therapy. Biochim Biophys Acta 2005;1756:127-44.
9. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: 949-54.
10. Emuss V, Garnett M, Mason C, Marais R. Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res 2005;65:9719-26.
11. Lee JW, Soung YH, Kim SY, et al. Mutational analysis of the ARAF gene in human cancers. APMIS 2005; 113:54-7.
12. Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 2005;23:6771-90.
13. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-67.
14. Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999;18:813-22.
15. Rinehart J, Adjei AA, Lorusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004;22: 4456-62.
16. Lorusso P, Krishnamurthi S, Rinehart J, et al. A Phase 1-2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer [abstract]. Proceedings of the American Society of Clinical Oncology Annual Meeting; 2005; Orlando, FL.
17. Chow L, Eckhardt S, Reid J, et al. A first in human dose-ranging study to assess the pharmacokinetics, pharmacodynamics, and toxicities of the Mek inhibitor, ARRY-142886 (AZD6244), in patients with advanced solid malignancies [abstract]. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2005; Philadelphia, PA.
18. Mansour SJ, Candia JM, Matsuura JE, Manning MC, Ahn NG. Interdependent domains controlling the enzymatic activity of mitogen-activated protein kinase kinase 1. Biochemistry 1996;35:15529-36.
19. Doyle M, Yeh T, Brown S, et al. Validation and use of a biomarker for clinical development of the MEK1/2 inhibitor ARRY-142886 (AZD6244) [abstract]. Proceedings of the American Society of Clinical Oncology Annual Meeting; 2005; Orlando, FL.
20. Lorusso PM, Adjei AA, Varterasian M, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005;23:5281-93.
21. Ohren JF, Chen H, Pavlovsky A, et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 2004;11:1192-7.
22. Ahn NG, Nahreini TS, Tolwinski NS, Resing KA. Pharmacologic inhibitors of MKK1 and MKK2. Methods Enzymol 2001;332:417-31.
23. Koo HM, VanBrocklin M, McWilliams MJ, Leppla SH, Duesbery NS, Woude GF. Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proc Natl Acad Sci U S A 2002;99: 3052-7.
24. Pohl G, Ho CL, Kurman RJ, Bristow R, Wang TL, Shih IM. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res 2005;65:1994-2000.
25. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2005;439:358-62.
26. Repasky GA, Chenette EJ, Der CJ. Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol 2004;14: 639-47.
27. Ballif BA, Blenis J. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ 2001;12:397-408.
28. Brassard DL, English JM, Malkowski M, Kirschmeier P, Nagabhushan TL, Bishop WR. Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras. Exp Cell Res 2002;273: 138-46.
29. 1 cell cycle arrest and apoptosis in tumor cells in which the pathway is constitutively activated: up-regulation of p27(Kip1). J Biol Chem 2001;276:2686-92.
30. Milella M, Kornblau SM, Estrov Z, et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 2001;108:851-9.
31. Mitsui H, Takuwa N, Maruyama T, et al. The MEK1-ERK map kinase pathway and the PI 3-kinase-Akt pathway independently mediate anti-apoptotic signals in HepG2 liver cancer cells. Int J Cancer 2001; 92:55-62.
32. Sebolt-Leopold JS, Dudley DT, Herrera R, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999;5: 810-6.
33. Winkler J, Lee P, Wallace E, et al. Anti-tumor activity, pharmacokinetic and pharmacodynamic effects of the MEK inhibitor ARRY-142886 (AZD6244) in a BxPC3 pancreatic tumor xenograft model [abstract]. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2004; Geneva, Switzerland.
34. Lee P, Wallace E, Yeh T, et al. ARRY-142886, a potent and selective MEK Inhibitor: III) Efficacy Against Human Xenograft Models Correlates with Decreased ERK phosphorylation [abstract]. Proceedings of the 95th Annual AACR Meeting; 2004; Orlando, FL.
35. Wallace E, Lyssikatos J, Blake J, et al. 4-(4-Bromo-2-fluorophenylamino)- 1-methyl-pyridin-2(1H)ones: potent and selective MEK 1,2 inhibitors [abstract]. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2005; Philadelphia, PA.
36. Lee P, Wallace E, Yeh T, et al. Demonstration of broad in vivo anti-tumor activity of ARRY-142886 (AZD6244), a potent and selective MEK inhibitor [abstract]. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2004; Geneva, Switzerland.